Tumor metabolism has emerged as an attractive target for therapy development, and several drugs including metformin (mitochondrial respiration), enasidenib (mutated IDH2), l-asparaginase, devimistat (PDH/αKGDH), CB-839 (glutaminase inhibitor) are being used in various cancer trials72–75. Here, IDH2 is linked to neoplasm.